Evidence map›Paper›PMID 25562657›Full record

ArticleNeurobiology of disease2015

Homeostatic regulation of KCC2 activity by the zinc receptor mZnR/GPR39 during seizures.

David Gilad, Sharon Shorer, Maya Ketzef, Alon Friedman, Israel Sekler, Elias Aizenman, Michal Hershfinkel

Open access · greenAbstract read
In one paragraph

Article in Neurobiology of disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 84 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Control of coronary vascular resistance by eicosanoids via a novel GPCR.American journal of physiology. Cell physiology · 2022
    Article
  17. The ZIP3 Zinc Transporter Is Localized to Mossy Fiber Terminals and Is Required for Kainate-Induced Degeneration of CA3 Neurons.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2022
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

David GiladDepartment of Physiology and Cell Biology, Ben-Gurion University of the Negev, Faculty of Health Sciences, Beer-Sheva, Israel.
Sharon ShorerDepartment of Physiology and Cell Biology, Ben-Gurion University of the Negev, Faculty of Health Sciences, Beer-Sheva, Israel.
Maya KetzefDepartment of Physiology and Cell Biology, Ben-Gurion University of the Negev, Faculty of Health Sciences, Beer-Sheva, Israel.
Alon FriedmanDepartment of Physiology and Cell Biology, Ben-Gurion University of the Negev, Faculty of Health Sciences, Beer-Sheva, Israel.
Israel SeklerDepartment of Physiology and Cell Biology, Ben-Gurion University of the Negev, Faculty of Health Sciences, Beer-Sheva, Israel.
Elias AizenmanDepartment of Physiology and Cell Biology, Ben-Gurion University of the Negev, Faculty of Health Sciences, Beer-Sheva, Israel; Department of Neurobiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Michal HershfinkelDepartment of Physiology and Cell Biology, Ben-Gurion University of the Negev, Faculty of Health Sciences, Beer-Sheva, Israel. Electronic address: hmichal@bgu.ac.il.
Ben-Gurion University of the Negev · ILUniversity of Pittsburgh · US

Funding

Liberation of Intracellular Zinc and Neuronal Cell DeathR01NS043277 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI AIZENMAN, ELIAS · 2002 to 2022
$8.2M
Liberation of Intracellular Zinc and Neuronal Cell DeathR56NS043277 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI AIZENMAN, ELIAS · 2007 to 2007
$371k
NINDS NIH HHS NS043277NINDS NIH HHS R01 NS043277NINDS NIH HHS R56 NS043277
6 · The paper itself

Abstract

The aim of this study was to investigate the role of the synaptic metabotropic zinc receptor mZnR/GPR39 in physiological adaptation to epileptic seizures. We previously demonstrated that synaptic activation of mZnR/GPR39 enhances inhibitory drive in the hippocampus by upregulating neuronal K(+)/Cl(-) co-transporter 2 (KCC2) activity. Here, we first show that mZnR/GPR39 knockout (KO) adult mice have dramatically enhanced susceptibility to seizures triggered by a single intraperitoneal injection of kainic acid, when compared to wild type (WT) littermates. Kainate also substantially enhances seizure-associated gamma oscillatory activity in juvenile mZnR/GPR39 KO hippocampal slices, a phenomenon that can be reproduced in WT tissue by extracellular Zn(2+) chelation. Importantly, kainate-induced synaptic Zn(2+) release enhances surface expression and transport activity of KCC2 in WT, but not mZnR/GPR39 KO hippocampal neurons. Kainate-dependent upregulation of KCC2 requires mZnR/GPR39 activation of the Gαq/phospholipase C/extracellular regulated kinase (ERK1/2) signaling cascade. We suggest that mZnR/GPR39-dependent upregulation of KCC2 activity provides homeostatic adaptation to an excitotoxic stimulus by increasing inhibition. As such, mZnR/GPR39 may provide a novel pharmacological target for dampening epileptic seizure activity.

Indexed as

Action PotentialsAnimalsAnimals, NewbornDisease Models, AnimalEdetic AcidExcitatory Amino Acid AgonistsFluoresceinsGamma RhythmGene Expression RegulationHippocampusHomeostasisIn Vitro TechniquesKainic AcidK Cl- CotransportersMiceMice, TransgenicEdetic AcidExcitatory Amino Acid AgonistsFluoresceinsGpr37 protein, mouseKainic AcidK Cl- CotransportersReceptors, G-Protein-CoupledSymportersZinczinpyr-1EpilepsyHippocampusKainic acidKCC2mZnR/GPR39SeizureZinc receptor

Identifiers

PMID25562657
PMCPMC4490144
OpenAlexW2015896990

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.